{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"682","upperLimit":"1519","value":"1166"},{"groupId":"OG001","lowerLimit":"403","upperLimit":"634","value":"519"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"121"}],"units":"Participants"}],"description":"PFS was defined as response duration while on maintenance therapy. It was the length of time during and after treatment in which a participant was living with the cancer that did not get worse.\n\nPFS was calculated from the date of randomization to the date of the first documented tumor progression or relapse.","dispersionType":"95% Confidence Interval","groups":[{"description":"Peginterferon α-2b 35 μg, weekly, subcutaneous (SC), until disease progression or relapse, or for up to a maximum of 5 years.","id":"OG000","title":"Peginterferon α-2b"},{"description":"Participants were observed and received no treatment","id":"OG001","title":"No Treatment"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat population (those who received at least one dose of study drug)","reportingStatus":"POSTED","timeFrame":"Baseline and up to 5 years (or to the date of the first documented tumor progression or relapse)","title":"Number of Days With Progression Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"Days"}